Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya11479010.26442/00403660.2022.10.201920Research ArticleProspects of using the nucleoside analogue riamilovir in patients with SARS-CoV-2 infectionMaltsevOleg V.dr.snegur@gmail.comhttps://orcid.org/0000-0002-6286-9946KasyanenkoKristina V.dr.snegur@gmail.comhttps://orcid.org/0000-0001-9294-7346KozlovKonstantin V.dr.snegur@gmail.comhttps://orcid.org/0000-0002-4398-7525ZhdanovKonstantin V.dr.snegur@gmail.comhttps://orcid.org/0000-0002-3679-1874LapikovIgor I.dr.snegur@gmail.comhttps://orcid.org/0000-0002-2185-3198Kirov Military Medical AcademyMIREA – Russian Technological University221120229410117111762211202222112022Copyright © 2022, Consilium Medicum2022<p><strong>Aim. </strong>To evaluate clinical efficacy of nucleoside analogues in therapy of moderate COVID-19 in in-patients.</p>
<p><strong>Materials and methods. </strong>Retrospective processing of 108 completed clinical cases with moderate novel coronavirus disease was carried out for the period 20202021. The duration of the disease at the time of admission did not exceed three days. Experimental group consisted of 53 patients who, in addition to standard therapy, were prescribed off-label riamilovir at a daily dosage of 1250 mg for 5 days by the decision of the medical commission. Comparison group included 55 patients who received a combination of umifenovir and ribavirin as antiviral therapy for 5 days. The duration of the main clinical manifestations of the disease, the indicators of clinical and biochemical blood tests, results of the SARS-CoV-2 virus RNA study using the nucleic acid amplification method (NAAT diagnostics).</p>
<p><strong>Results. </strong>Significantly faster achievement of clinical improvement in the group of patients treated with riamilovir was shown, as well as faster sanitation from SARS-CoV-2 virus based on the results of etiological testing.</p>
<p><strong>Conclusion. </strong>The use of riamilovir for the treatment of patients with moderate novel coronavirus infection (COVID-19) resulted in a significant reduction of general infectious syndromes and respiratory symptoms. Patients from the experimental group significantly faster achieved clinical recovery and sanitation from the pathogen according to the results of NAAT diagnostics.</p>COVID-19novel coronavirus infectionriamilovirantiviral therapyumifenovirribavirinCOVID-19новая коронавирусная инфекцияриамиловирпротивовирусная терапияумифеновиррибавирин[COVID-19 Coronavirus pandemic. Reported Cases and Deaths by Country, Territory, or Conveyance. Situation Report. Available at: https://ourworldindata.org/explorers/coronavirus-data explorer?facet=none&Metric=Confirmed+deaths&Interval=7-day+rolling+average&Relative+to+Population=true&Color+by+test+positivity=false&country=~RUS. Accessed: 05.10.2022.][COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Available at: https://coronavirus.jhu.edu/map.html. Accessed: 05.10.2022.][Zumla A, Chan JFW, Azhar EI, et al. Coronaviruses – drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327-47. DOI:10.1038/nrd.2015.37][Smith EC, Blanc H, Surdel MC, et al. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog. 2013;9(8):e1003565. DOI:10.1371/journal.ppat.1003565][Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):343. DOI:10.1371/journal.pmed.0030343][Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31(1):69-75. DOI:10.1016/j.jcv.2004.03.003][Hassanipour S, Arab-Zozani M, Amani B, et al. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021;11(1):11022. DOI:10.1038/s41598-021-90551-6][Özlüşen B, Kozan Ş, Akcan RE, et al. Effectiveness of favipiravir in COVID-19: a live systematic review. Eur J Clin Microbiol Infect Dis. 2021;40(12):2575-83. DOI:10.1007/s10096-021-04307-1][Лиознов Д.А., Токин И.И., Зубкова Т.Г., и др. Практика применения отечественного противовирусного препарата в этиотропной терапии острой респираторной вирусной инфекции. Терапевтический архив. 2020;92(12):160-4 [Lioznov DA, Tokin II, Zubkova TG, et al. The practice of using a domestic antiviral drug in the etiotropic therapy of acute respiratory viral infection. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(12):160-4 (in Russian)]. DOI:10.26442/00403660.2020.12.200427][Wu X, Yu K, Wang Y. Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial. Engineering (Beijing). 2020;6(10):1185-91. DOI:10.1016/j.eng.2020.08.011][Сабитов А.У., Белоусов В.В., Един А.С., и др. Практический опыт применения препарата Риамиловир в лечении пациентов с COVID-19 средней степени тяжести. Антибиотики и химиотерапия. 2020;65(7-8):27-30 [Sabitov AU, Belousov VV, Edin AS, et al. Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19. Antibiotics and Chemotherapy. 2020;65(7-8):27-30 (in Russian)]. DOI:10.37489/0235-2990-2020-65-7-8-27-30][Касьяненко К.В., Козлов К.В., Мальцев О.В., и др. Оценка эффективности Риамиловира в комплексной терапии больных COVID-19. Терапевтический архив. 2021;93(3):290-4 [Kasyanenko KV, Kozlov KV, Maltsev OV, et al. Evaluation of the effectiveness of Riamilovir in the complex therapy of patients with COVID-19. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(3):290-4 (in Russian)]. DOI:10.26442/00403660.2021.03.200719][Авдеев С.Н., Адамян Л.В., Алексеева Е.И., и др. Профилактика, диагностика и лечение новой коронавирусной инфекции (Covid-19). Временные методические рекомендации. 2022;15. Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/%D0%92%D0%9C%D0%A0_COVID-19_V15.pdf. Ссылка активна на 05.09.2022 [Avdeev SN, Adamyan LV, Alekseeva EI, et al. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (Covid-19). Vremennye metodicheskie rekomendatsii. 2022;15. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/%D0%92%D0%9C%D0%A0_COVID-19_V15.pdf. Accessed: 05.09.2022 (in Russian)].][Mudatsir M, Fajar JK, Wulandari L, et al. Predictors of COVID-19 severity: a systematic review and meta-analysis. F1000Research. 2021;9(1107). DOI:10.12688/f1000research.26186.2][Силкина У.И., Баландин В.А. Дискриминантный анализ параметров вариационной пульсометрии. Российский технологический журнал. 2020;8(3):81-91 [Silkina UI, Balandin VA. Discriminant analysis of variational pulsometry parameters. Russian Technological Journal. 2020;8(3):81-91 (in Russian)]. DOI:10.32362/2500-316X-2020-8-3-81-91][Sirohiya P, Vig S, Pandey K, et al. A Correlation Analysis of Peripheral Oxygen Saturation and Arterial Oxygen Saturation Among COVID-19 Patients. Cureus. 2022;14(4):e24005. DOI:10.7759/cureus.24005]